M.D. Sass LLC Has $64.23 Million Stock Position in Danaher Corporation (NYSE:DHR)

M.D. Sass LLC boosted its holdings in Danaher Corporation (NYSE:DHR) by 100.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 313,321 shares of the conglomerate’s stock after purchasing an additional 157,334 shares during the quarter. Danaher makes up approximately 5.7% of M.D. Sass LLC’s holdings, making the stock its 5th biggest position. M.D. Sass LLC’s holdings in Danaher were worth $64,231,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in DHR. GHP Investment Advisors Inc. boosted its stake in Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 99 shares during the period. Heck Capital Advisors LLC bought a new position in Danaher in the 4th quarter worth approximately $27,000. Sierra Ocean LLC boosted its stake in Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock worth $29,000 after purchasing an additional 76 shares during the period. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Danaher during the 1st quarter worth approximately $31,000. Finally, Hurley Capital LLC purchased a new stake in shares of Danaher during the 4th quarter worth approximately $34,000. 79.05% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman owned 3,105,808 shares of the company’s stock, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of Danaher stock opened at $197.08 on Friday. The stock’s fifty day moving average is $197.49 and its two-hundred day moving average is $202.44. The company has a market capitalization of $141.12 billion, a PE ratio of 41.93, a price-to-earnings-growth ratio of 2.74 and a beta of 0.73. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The business had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter in the prior year, the company earned $1.72 EPS. The business’s revenue was up 3.4% compared to the same quarter last year. As a group, analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, July 25th. Stockholders of record on Friday, June 27th were given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s payout ratio is 27.23%.

Wall Street Analyst Weigh In

DHR has been the topic of several recent research reports. Argus decreased their price objective on Danaher from $260.00 to $240.00 in a report on Wednesday, April 23rd. Barclays reaffirmed an “overweight” rating and set a $225.00 price objective (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Wolfe Research decreased their price objective on Danaher from $275.00 to $220.00 and set an “outperform” rating on the stock in a report on Monday, April 7th. Deutsche Bank Aktiengesellschaft decreased their price objective on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Finally, Leerink Partners upped their price objective on Danaher from $225.00 to $230.00 and gave the stock an “outperform” rating in a report on Wednesday, April 23rd. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $247.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.